LONDON, April 7, 2014 /PRNewswire/ --

On Friday, April 04, 2014, the NASDAQ Composite ended at 4,127.73, down 2.60%, the Dow Jones Industrial Average declined 0.96% to 16,412.71, and the S&P 500 closed at 1,865.09, down 1.25%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.79, down 1.54%, and has fallen by 2.23% in the last one month. Investor-Edge has initiated coverage on the following equities: Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY), Johnson & Johnson (NYSE: JNJ) and Eli Lilly & Co. (NYSE: LLY). Free technical research on MRK, BMY, JNJ and LLY can be downloaded upon signing up at:

http://www.investor-edge.com/843-register


Merck & Co. Inc.'s stock fell 0.16% on Friday, closing at $56.12, after oscillating between $56.09 and $56.72. A total of 10.41 million shares were traded, which is below its three months average volume of 12.81 million shares. Merck & Co. Inc.'s shares have surged 12.83% in the previous three months and 12.13% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages. Merck & Co. Inc.'s 50-day moving average of $55.39 is above its 200-day moving average of $49.95. Furthermore, the company's stock is trading at a PE ratio of 16.13 and has a Relative Strength Index (RSI) of 52.45. Sign up today to read free research on MRK at:

http://www.investor-edge.com/843-MRK-07Apr2014.pdf


Shares in Bristol-Myers Squibb Co. witnessed a trading volume of 8.44 million shares on Friday, as compared with its three months average volume of 9.41 million shares. The stock ended the day at an intra-day low of $49.89, down 1.93%, after trading between $49.89 and $51.71. Shares in Bristol-Myers Squibb Co. have lost 10.21% in the last one month and 6.13% on YTD basis. The stock is trading above its 200-day moving average. Bristol-Myers Squibb Co.'s 50-day moving average of $52.74 is above its 200-day moving average of $49.19. Additionally, the company's shares are trading at a PE ratio of 29.74 and have an RSI of 32.24. Sign up today to read free research on BMY at:

http://www.investor-edge.com/843-BMY-07Apr2014.pdf


On Friday, shares in Johnson & Johnson gained 0.16% finishing the session at $98.42, after hitting a new 52-week high of $99.38. The stock recorded a trading volume of 10.31 million shares which is above its three months average volume of $8.83 million shares. The stock fluctuated between $98.32 and $99.38 during the session. Johnson & Johnson's shares have advanced 5.95% in the last one month, 6.60% in the previous three months, and 7.46% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. Johnson & Johnson's 50-day moving average of $92.81 is above its 200-day moving average of $91.42. Moreover, the company's shares are trading at a PE ratio of 17.92 and have RSI of 72.00. Sign up today to read free research on JNJ at:

http://www.investor-edge.com/843-JNJ-07Apr2014.pdf


Eli Lilly & Co.'s stock recorded a trading volume of 5.18 million shares, as compared with its three months average volume of 5.73 million shares. The stock ended Friday's session at $59.01, up 0.07%, and at an intraday trading range of $58.93 and $59.96. Eli Lilly & Co.'s shares have gained 0.49% in the last one month, 14.52% in the previous three months, and 15.71% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. Eli Lilly & Co.'s 50-day moving average of $56.93 is above its 200-day moving average of $52.71. Further, the company's shares are trading at a PE ratio of 13.35 and have an RSI of 59.08. Sign up today to read free research on LLY at:

http://www.investor-edge.com/843-LLY-07Apr2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Copyright 2014 PR Newswire

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Bristol Myers Squibb Charts.